Apixaban = Dead in the Water! Hot off the press!

Discussion in 'Pfizer' started by Anonymous, Jul 25, 2011 at 9:24 AM.

Tags: Add Tags
  1. Anonymous

    Anonymous Guest

    So, the drug is supposed to be safer then current therapy... this is the second stusy showing an increase in bleeding vs. current therapy. With BI's drug out and J&J drug just approved without these bleeding issues. We are lucky of this drug comes to market.

    GET READY FOR THE AXE TO DROP KIDDIES!!!

    •The researchers said 1.3 percent of those taking Eliquis had major bleeding, compared with 0.5 percent of those receiving the placebo. Also, more patients taking Eliquis had bleeding into the brain and died from uncontrollable bleeding than patients receiving placebo, according to Alexander.
     

  2. Anonymous

    Anonymous Guest

    Nothing has changed.

    This is the same study that was reported in November (APPRAISE-2). This was never the primary indication the companies were shooting for.
     
  3. Anonymous

    Anonymous Guest

    Pfear the beast coming. Pfizer!
     
  4. Anonymous

    Anonymous Guest

    Please post the some of the facts: it's not apixiban treatmeant alone


    The conclusion: "Combination treatment with an anticoagulant and dual antiplatelet therapy should be avoided unless there is a clear indication for both, as in some patients with atrial fibrillation," Alexander said.
     
  5. Anonymous

    Anonymous Guest

    Umm, something has changed, the NEJM study was published yesterday.


    Anti-Clotting Drug May Cause Severe Bleeding With No Benefit - (Yahoo!Health via NewsPoints Desk)
    (Ref: Yahoo!Health)
    July 24th, 2011

    http://www.firstwordpharma.com/node/891607
     
  6. Anonymous

    Anonymous Guest

  7. Anonymous

    Anonymous Guest

  8. Anonymous

    Anonymous Guest

    You are a complete douche. Where the hell have you been? Old news. Eliquis is still projected to be the better of the three new AC's.
     
  9. Anonymous

    Anonymous Guest

    Great news. This will be a great addition to go with bextra, exubera, torcetrapib and trovan. It keeps getting better and better
     
  10. Anonymous

    Anonymous Guest

    Absolutely! Clearly the editors at the NEJM are pharma hacks who are easily bought off by big companies to only publish positive studies...Oops...guess that's not happening here.
     
  11. Anonymous

    Anonymous Guest

    Go troll elsewhere.

    What other trial was conducted where they added an Xa inhibitor to patients already taking aspirin and plavix?

    And again, this isn't the second trial showing increased bleeding, it is the first.
     
  12. Anonymous

    Anonymous Guest

    no worries, mate. PFE got this under control.
     
  13. Anonymous

    Anonymous Guest

    e-LICK-we-US?
     
  14. Anonymous

    Anonymous Guest

    Where did I ever say it was the second?
     
  15. Anonymous

    Anonymous Guest

    Gee you must get "First Word". No new info- Trial done in ACS, Check the stock price Scoop. I will agree that if bad news does come out on this drug for primary indications, Primary Care division is toast.
     
  16. Anonymous

    Anonymous Guest

    Brilliant deduction Einstein, the link went to "First Word".
     
  17. Anonymous

    Anonymous Guest

    So..... BIs drug didn't have this.,, and bayer/J&j drug doesn't have this. Ya really think this drug is going to come to. Market when you have 2 competing drugs that don't have an increase in bleeding ???

    Oh... By the way...isn't this the reason these drugs are so hot??? Less bleeding??

    Not good people!!! One word!

    RUN FOREST!!! RUN!!!

    LOL
     
  18. Anonymous

    Anonymous Guest

    You simply don't know what you are talking about. All of the new ACs have bleeding issues. It comes with the territory dumbass. This drug will come out next year and will be the class leader within 12 months. Mark it down.
     
  19. Anonymous

    Anonymous Guest

    Looks like somebody hit a nerve. Go back to "First Word" and find out some new earth shattering info. Hot off the press with data from November 2010.
     
  20. Anonymous

    Anonymous Guest

    Because they did not try a trial in ACS. Now why don't You run back to the BI board.